Project Grant R01HL177971
Award Date
1/1/25
Completion Date
11/30/28
Dollars Obligated
$750K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to study the role of plasma cells in chronic rejection after lung transplantation. The $2,241,717 grant, awarded on September 2, 2024, will be performed by the University of Pittsburgh over a 4-year period ending on May 31, 2028. The key objectives of this research are to: 1) Provide a comprehensive analysis of B cell and...
This $1,564,220 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to develop an imaging-compatible ex vivo lung perfusion (EVLP) system for assessing structural, functional, and metabolic biomarkers in donor lungs. The goal is to optimize EVLP parameters and apply injury-specific treatment strategies to recondition "marginal" donor lungs with defects like atelectasis,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
This $2,803,961 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a collaborative research effort to investigate the mechanisms underlying primary graft dysfunction (PGD) and chronic lung allograft dysfunction (CLAD) in lung transplant recipients. The research team at Northwestern University will conduct four interrelated projects to better understand the role of lung-restricted alloantibodies,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $772,400 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital of Philadelphia (CHOP) to develop decellularized cartilage and progenitor cells for laryngotracheal reconstruction. The project aims to address the high failure rate and incidence of restenosis in pediatric laryngotracheal reconstruction procedures by engineering alternative graft options. The research will focus on producing...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $865,694 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct research on controlling neuropilin-2 (NRP2) signaling to improve lymphatic function. The key objectives are to: 1) Alter NRP2 expression and ligand-dependent functions in the skin to sustain proper fluid drainage and...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...
This Project Grant award of $799,354 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to comprehensively understand and pharmacologically target the necroptotic pathways in both the donor and recipient lungs to reduce the incidence of primary graft dysfunction (PGD) in lung transplantation. The research has two specific aims: 1) Exploring the role of TNF-α-induced autocrine necroptosis in monocyte-derived alveolar...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $721,826 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant funds research to identify molecular mechanisms regulating the function of alveolar matrix fibroblasts and their role in supporting vascular network formation during postnatal lung development. The research aims to elucidate the transcriptional regulator MEOX2 and...